サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1801228

前立腺肥大症治療の市場規模、シェア、動向、予測：治療タイプ別、地域別、2025年～2033年

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 137 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.02円
前立腺肥大症治療の市場規模、シェア、動向、予測：治療タイプ別、地域別、2025年～2033年
出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前立腺肥大症治療の世界市場規模は2024年に125億米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに185億米ドルに達し、2025年から2033年にかけて4.4%のCAGRを示すと予測しています。現在、北米が市場を独占しており、2024年には34.8%以上の大きなシェアを占めています。この市場を牽引しているのは、高齢男性における前立腺肥大症の有病率の上昇、低侵襲手術の進歩、薬剤製剤の改良などです。レーザー治療や併用治療における技術革新が患者の治療成績をさらに向上させ、前立腺肥大症治療市場のシェアを高めています。

前立腺肥大症（BPH）治療市場の主な促進要因は、高齢化する男性人口におけるBPHの有病率の増加、泌尿器科の健康に対する意識の高まり、低侵襲治療法の進歩です。BPHが排尿症状や合併症などQOLに与える影響から、効果的な治療法への需要が高まっています。また、レーザー療法を含む開発により、薬剤の処方や組み合わせが改善され、医療アクセスの増加や先進地域における有利な償還政策とともに市場の成長を高めています。例えば、2024年9月、Royal Surrey NHS Foundation Trustは、50歳以上の男性の約50％が罹患している良性前立腺肥大症に対するエコーレーザー治療を導入しました。Prostate Project慈善団体により資金提供されたこの低侵襲手術は、迅速な回復と最小限の副作用を可能にし、患者のQOLを向上させ、入院期間を短縮します。このような進歩により、前立腺肥大症治療市場の見通しは明るいです。

米国の前立腺肥大症（BPH）治療市場の主な促進要因は、男性人口の高齢化に伴うBPHの有病率の高さと、泌尿器科の健康に対する意識の高まりです。また、レーザーを用いた治療や前立腺動脈塞栓術などの低侵襲手技の進歩も、その効率性と回復時間の早さに基づいて人気を博しています。例えば、2023年7月、アドベンティスト・ヘルス・ポートランド社は、水とロボットの精度を用いた前立腺肥大症（BPH）の低侵襲治療であるアクアブレーション療法を開始しました。この革新的な治療法は、前立腺肥大の症状に悩む男性にとって新たな選択肢となります。また、改善された薬物療法や併用療法も利用できるようになり、治療の選択肢の幅が広がっています。これは米国における重要な前立腺肥大症治療市場動向の一つです。

前立腺肥大症治療市場動向：

低侵襲治療へのシフト

前立腺肥大症の治療において、低侵襲手術が用いられるようになってきています。米国国立衛生研究所（NIH）によると、中等度から重度の前立腺肥大症の症状を持つ男性の推定30％が何らかの形で低侵襲治療を受けています。技術としては、レーザー治療、TUMT、TURPなどがあります。これらは、最小限の回復時間で効果が証明されているため、患者にも医師にも受け入れられています。このような治療法では、周囲の組織へのダメージを最小限に抑えながら治療が行われるため、出血や感染などの合併症が少なくなります。さらに、従来の開腹手術に比べ、患者は痛みが少なく、通常の活動への復帰も早いです。これは、より侵襲の少ない外来患者中心のサービスを求めるヘルスケア分野の一般的な動向と一致しています。ホルミウムレーザー核出術やグリーンライトレーザー治療のような技術の成長は、シフトする市場にさらに拍車をかけ、現在では、長期入院や侵襲的な手術を受けたくない患者に代替手段が提供されています。このような手技の受け入れ拡大は、やがて前立腺肥大症治療市場の需要拡大につながると思われます。

先進的薬物療法の登場

BPH治療の状況は、新たな薬理療法の出現によって大きく変わりつつあります。新しい薬剤クラス別や併用療法は、より少ない副作用でより良い症状管理を目指すものです。米国国立糖尿病・消化器・腎臓病研究所（NIDDK）によると、51～60歳の男性の50％近く、80歳以上の男性の90％近くがBPHに罹患しており、薬理学的治療の必要性が高まっています。α遮断薬や5α還元酵素阻害薬などの伝統的な治療がその役割を果たし続けている一方で、α遮断薬や5-ARIなどの先進的な薬物療法は一般的な治療法であるが、めまいや性機能障害などの顕著な副作用を伴う。アボダートやシアリスのような治療薬の特許が切れたことで、ジェネリック医薬品にチャンスが広がり、手頃な価格の代替品が提供され、薬物治療市場の成長を促しています。PDE5阻害薬や新規のデュアルターゲット治療薬のような薬剤の開発への取り組みが増加しており、症状緩和へのより総合的なアプローチを提供しています。これらの先進的な薬剤は、前立腺だけでなく、BPHの一般的な併存疾患である勃起不全も治療します。より多くの治療法が利用できるようになったことで、これらの患者は自分の健康状態や症状により適した、個別の症状に基づいた治療計画を利用することができます。さらに、効能を向上させ、有害な副作用を最小限に抑えるために既存の医薬品を併用するという動向も見られます。生物学的製剤や遺伝子治療の臨床試験への参入により、BPHの状況はさらに劇的に変化し、患者に効果的な長期治療が提供されるようになると思われます。

老年人口の増加

世界の老年人口はBPH治療市場の主要な成長促進要因です。高齢になるにつれてBPHの発症率は増加し、50歳以上の男性に最も多いです。1974年から2024年にかけて、世界の65歳人口の割合はほぼ倍増し、5.5%から10.3%に上昇します。国連の人口統計学的推計によれば、2024年から2074年にかけて、この数字はさらに倍増し、20.7％に達します。同時に、80歳以上の人口は現在の3倍を超えると予想されています。先進地域では高齢者人口が大幅に増加し、前立腺肥大症の治療を必要とする人口が大幅に拡大すると予想されています。このような人口動態の変化は、効果的でありながら手ごろな価格の治療介入を求め、ヘルスケアシステムにさらなる負担をかけると思われます。世界人口の高齢化はBPH治療に対する需要を煽り、ジェネリック医薬品は患者のアクセスや全体的な治療売上を増加させる低コストの選択肢を提供しています。高齢の男性は高血圧や糖尿病などの合併症を抱えやすいです。このような併存疾患はBPHの管理をさらに複雑にするため、一度に複数の健康上の要求を満たすオーダーメイドのレジメンを求める原動力となっています。高齢者はめまいや転倒リスクの増加など、BPH治療による副作用を受けやすいです。高齢化が進む中、より安全な治療によってこれらのリスクを最小限に抑えることがヘルスケアにおける優先事項となってきています。そのため、製薬会社やヘルスケア企業は、BPHの症状を治療し、一般的に患者、特に高齢者の生活の質を向上させる医薬品の開発を進めています。高齢化社会は、外科的治療だけでなく薬理学的治療の需要も高めることで、今後も増え続け、市場に影響を与えると予測されています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の前立腺肥大症治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 薬剤クラス
    • 主な種類
      • アルファ遮断薬
      • 5-α還元酵素阻害剤（5-ARI）
      • ホスホジエステラーゼ5酵素阻害剤
      • その他
  • 低侵襲手術
    • 主な種類
      • 経尿道的前立腺切除術（TURP）
      • 経尿道的前立腺切開術（TUIP）
      • 経尿道マイクロ波温熱療法（TUMT）
      • ロボット手術
      • 前立腺尿道リフト
      • その他
  • レーザー療法
  • その他

第7章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第8章 SWOT分析

第9章 バリューチェーン分析

第10章 ポーターのファイブフォース分析

第11章 価格分析

第12章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Allergan plc（AbbVie Inc.）
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH（C.H. Boehringer Sohn AG & Ko. KG）
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2024
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players
目次
Product Code: SR112025A2898

The global benign prostatic hyperplasia treatment market size was valued at USD 12.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.5 Billion by 2033, exhibiting a CAGR of 4.4% during 2025-2033. North America currently dominates the market, holding a significant share of over 34.8% in 2024. The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.

Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.

The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.

Benign Prostatic Hyperplasia Treatment Market Trends:

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.

Emergence of Advanced Drug Therapies

The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.

Rising Geriatric Population

The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.

Benign Prostatic Hyperplasia Treatment Industry Segmentation:

Analysis by Treatment Type:

  • Drug Class
    • Alpha-Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally Invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Robotic Surgeries
    • Prostatic Urethral Lifts
    • Others
  • Laser Therapy
  • Others

Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.

Key Regional Takeaways:

United States Benign Prostatic Hyperplasia Treatment Market

In 2024, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.

Europe Benign Prostatic Hyperplasia Treatment Market

The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.

Asia Pacific Benign Prostatic Hyperplasia Treatment Market

The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.

Latin America Benign Prostatic Hyperplasia Treatment Market

Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.

Middle East and Africa Benign Prostatic Hyperplasia Treatment Market

The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.

Competitive Landscape:

The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.

The report provides a comprehensive analysis of the competitive landscape in the benign prostatic hyperplasia treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan Plc (AbbVie Inc.)
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
  • Boston Scientific Corporation
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the benign prostatic hyperplasia treatment market?
  • 2.What are the market drivers for benign prostatic hyperplasia (BHP) treatment devices?
  • 3.What is the benign prostatic hyperplasia (BPH) treatment device market growth?
  • 4.What are the key factors driving the benign prostatic hyperplasia treatment market?
  • 5.Which region accounts for the largest benign prostatic hyperplasia treatment market share?
  • 6.Which are the leading companies in the global benign prostatic hyperplasia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis